Everest Medicines has entered a share purchase agreement to acquire Hasten Biopharmaceuticals (SG) Pte. Ltd., aiming to expand its commercial presence in the Asia Pacific region and strengthen its chronic disease portfolio.

• Acquisition: Agreement to acquire the entire equity interest via EverSea Medicines (Singapore) Pte. Ltd., including rights to 14 chronic disease products across Asia Pacific.
• Financials: Total consideration of USD250 million, payable in three instalments; 2025 normalised revenue of US$82.2 million and EBITDA of US$27.2 million for the target entity.
• Impact: Upon closing, the entity will become an indirect wholly-owned subsidiary, with financial results consolidated into Everest Medicines’ statements.

This summary is based on a press release issued by Everest Medicines.

Image for illustrative purposes only. Source: Canva.